Eris Lifesciences is now one of the fastest growing pharmaceutical companies in the country. It was founded by Amit Bakshi and team in 2007 with corporate office at Ahmedabad, Gujarat. It is a Specialty focused pharmaceutical company engaged in research, development, marketing, manufacturing and selling of branded generics within the chronic and acute categories of the Indian Branded Formulations market such as: cardiovascular; anti–diabetes; vitamins; gastroenterology and gynaecology.
Eris product portfolio is primarily focused on therapeutic areas including Cardiology, Diabetology, Endocrinology, Gastroenterology, ENT, Orthopedics, Pediatrics and Gynecology segments. With a team of over 1500 people across India dedicated to these specialities and a total of over 2300 employees, the network of Eris Lifesciences consists of 22 Sales Depots and over 900 stockists, enabling it to achieve presence across India for distribution of our products. It is the youngest company to feature amongst Top 35 companies in the Indian Branded Formulations Market.
Strengths of Eris Lifesciences:
- Focus on developing products in the chronic and acute category which are linked to lifestyle related disorders
- Product portfolio of 80 mother brand groups, as of March 31, 2017
- Portfolio primarily focused on therapeutic areas requiring the intervention of specials and super specialists
- Multi-faceted product selection and engagement model leading to growth in prescriptions
- Strong sales, marketing and distribution capabilities
Eris Lifesciences has a portfolio of high volume and leading brands which include Glimisave (Anti-Diabetes), Eritel (Hypertension), Rabonik (Gastroenterology), Tayo (Vitamin D deficiency in Metabolic disorders), Remylin (Diabetic Neuropathy), Olmin (Hypertension), Atorsave (Lipid Lowering), Lnbloc (Hypertension), Crevast (Lipid Lowering) and Cyblex (Anti-Diabetes).
Eris Lifesciences is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the Red Herring Prospectus dated June 06, 2017 (“RHP”) with the Registrar of Companies, Gujarat (“RoC”). The RHP (Red Herring Prospectus) is available on the website of the SEBI at www.sebi.gov.in, as well on the websites of the Book Running Lead Managers i.e., www.axiscapital.co.in, www.credit-suisse.com/in/IPO, www.online.citibank.co.in/rhtm/citigroupglobalscreen1.htm and the websites of the Stock Exchanges at BSE at www.bseindia.com and NSE at www.nseindia.com. Any potential investor should note that investment in Equity Shares involves a high degree of risk, for details potential investors should refer to the section titled “Risk Factors” beginning on page 16 of the RHP. Potential investors should not rely on the DRHP (Draft Red Herring Prospectus) filed with SEBI for making any investment decision.
This announcement has been prepared for publication in India and may not be released in the United States. This material is not an offer for sale of the equity shares in the United States. The equity shares being offered in the initial public offer have not been and will not be registered under the U.S.Securities Act of 1933, as amended (the “U.S.Securities Act”) or any state securities laws in the United States, and unless so registered may not be offered or sold within the United States, except pursuant to an exemption fron, or in a transaction not subject to, the registration requirements of the U.S.Securities Act and the applicable state securities laws. Accordingly, such equity shares are being offered and sold (i) outside the United States in offshore transactions in reliance on Regulation S under the U.S.Securities Act and the applicable laws of jurisdictions where those offers and sales occer, and (ii) to ‘qualified institutional buyers’ (as defined in Rule 144A under the U.S.Securities Act), pursuat to the private placement exemption set out in Section 4(a) of the U.S.Securities Act.
Update, 2nd advert: Eris ‘Tendia CGM on call’ initiative supports doctors in taking important diabetes treatment decisions.